Merck Unveils New M Lab™ Collaboration Center in Korea
Merck announced the opening of an M Lab™ Collaboration Center in the Songdo district of Incheon, Korea, one of the fastest growing biotech hubs in Asia. The center provides biopharmaceutical manufacturers with a shared, exploratory environment where they can closely collaborate with Merck scientists and engineers to solve their toughest challenges and accelerate development and production of new therapies.
Merck KGaA
“With a rapidly growing biopharmaceutical industry in Korea and demand for novel and cost-effective therapies worldwide, there is a clear need for innovative concepts like our M Lab™ Collaboration Centers,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “At our new center in Incheon, our customers will benefit from our deep technical expertise to develop processes for manufacturing drugs faster, safer and more effectively than ever before.”
The new M Lab™ Collaboration Center replaces a smaller facility in Seoul and will better suit the needs of Korea’s growing biopharmaceutical market. The new, state-of-the-art center will include a simulated manufacturing environment and offer full end-to-end process development support. In addition, education on best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer will be available to customers.
The new M Lab™ Collaboration Center in Incheon is one of nine such centers around the world. Each center allows pharmaceutical manufacturers to explore new ways to increase productivity, improve processes and mitigate risks by giving them access to a team of experts. Customers have access to sizing and simulation tools and methodologies as well as analytical and modeling support. Formal bioprocessing educational courses are also available, including traditional classroom-style training and interactive, hands-on sessions.
Other news from the department business & finance
